Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome

Subirá, Dolores ; Alhan, Canan ; Oelschlaegel, Uta ; Porwit, Anna LU ; Psarra, Katherina ; Westers, Theresia M. ; Golbano, Nuria ; Nilsson, Lars ; van de Loosdrecht, Arjan A. and de Miguel, Dunia (2021) In Annals of Hematology 100(7). p.1711-1722
Abstract

5-Azacitidine (AZA) therapy is used in high-risk myelodysplastic syndrome (MDS) patients who often show abnormalities in their immunophenotype. We explored the potential impact of AZA on these immunophenotypic abnormalities in serial bone marrow studies performed in 81 patients from five centers. We compared the immunophenotypic features before and after therapy with AZA, established definitions consistent with flow cytometry immunophenotyping (FCI) improvement, and explored its clinical significance. After a median of 6 cycles of AZA, 41% of patients showed a FCI improvement and this finding associated with best possible clinical response (P < 0.001). FCI improvement also correlated with hematological improvement (HI) (53/78... (More)

5-Azacitidine (AZA) therapy is used in high-risk myelodysplastic syndrome (MDS) patients who often show abnormalities in their immunophenotype. We explored the potential impact of AZA on these immunophenotypic abnormalities in serial bone marrow studies performed in 81 patients from five centers. We compared the immunophenotypic features before and after therapy with AZA, established definitions consistent with flow cytometry immunophenotyping (FCI) improvement, and explored its clinical significance. After a median of 6 cycles of AZA, 41% of patients showed a FCI improvement and this finding associated with best possible clinical response (P < 0.001). FCI improvement also correlated with hematological improvement (HI) (53/78 patients; 68%), independently of their eligibility for stem cell transplantation. Among patients who achieved a HI after 6 cycles of AZA, the probability of maintaining this response at 12 cycles of AZA was twice as large (67%) for those patients who also achieved a FCI improvement after 6 cycles of AZA as compared to patients who did not (33%, P < 0.01). These findings support that monitoring of the immunophenotypic abnormalities during therapy with AZA may assist in redefining the quality of response in patients with MDS.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
5-Azacitidine response, Flow cytometry, Immunophenotype, MDS, Myelodysplastic syndrome
in
Annals of Hematology
volume
100
issue
7
pages
12 pages
publisher
Springer
external identifiers
  • scopus:85099304727
  • pmid:33423077
ISSN
0939-5555
DOI
10.1007/s00277-021-04411-4
language
English
LU publication?
yes
id
c8f63461-ff39-44a7-b5fc-cd494afcb87c
date added to LUP
2021-01-25 13:12:11
date last changed
2024-06-13 06:13:18
@article{c8f63461-ff39-44a7-b5fc-cd494afcb87c,
  abstract     = {{<p>5-Azacitidine (AZA) therapy is used in high-risk myelodysplastic syndrome (MDS) patients who often show abnormalities in their immunophenotype. We explored the potential impact of AZA on these immunophenotypic abnormalities in serial bone marrow studies performed in 81 patients from five centers. We compared the immunophenotypic features before and after therapy with AZA, established definitions consistent with flow cytometry immunophenotyping (FCI) improvement, and explored its clinical significance. After a median of 6 cycles of AZA, 41% of patients showed a FCI improvement and this finding associated with best possible clinical response (P &lt; 0.001). FCI improvement also correlated with hematological improvement (HI) (53/78 patients; 68%), independently of their eligibility for stem cell transplantation. Among patients who achieved a HI after 6 cycles of AZA, the probability of maintaining this response at 12 cycles of AZA was twice as large (67%) for those patients who also achieved a FCI improvement after 6 cycles of AZA as compared to patients who did not (33%, P &lt; 0.01). These findings support that monitoring of the immunophenotypic abnormalities during therapy with AZA may assist in redefining the quality of response in patients with MDS.</p>}},
  author       = {{Subirá, Dolores and Alhan, Canan and Oelschlaegel, Uta and Porwit, Anna and Psarra, Katherina and Westers, Theresia M. and Golbano, Nuria and Nilsson, Lars and van de Loosdrecht, Arjan A. and de Miguel, Dunia}},
  issn         = {{0939-5555}},
  keywords     = {{5-Azacitidine response; Flow cytometry; Immunophenotype; MDS; Myelodysplastic syndrome}},
  language     = {{eng}},
  month        = {{07}},
  number       = {{7}},
  pages        = {{1711--1722}},
  publisher    = {{Springer}},
  series       = {{Annals of Hematology}},
  title        = {{Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome}},
  url          = {{http://dx.doi.org/10.1007/s00277-021-04411-4}},
  doi          = {{10.1007/s00277-021-04411-4}},
  volume       = {{100}},
  year         = {{2021}},
}